Olema Oncology's Upcoming Presentation at Healthcare Conference

Author: Ryan Hughes Updated: 02-19-2025 04:55 PM

Olema Oncology's Upcoming Conference Presentation

Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", NASDAQ: OLMA) is poised to make a significant impression at the upcoming TD Cowen 45th Annual Health Care Conference. On Wednesday, March 5, 2025, at 10:30 a.m. ET, President and CEO, Sean P. Bohen, M.D., Ph.D., will be delivering a presentation that promises to highlight the innovative approaches Olema is taking in the realm of breast cancer treatment.

Live Webcast Information

For those interested in attending virtually, a live webcast of the presentation will be accessible under the Events and Presentations section of Olema's Investor Relations website. This is an exciting opportunity for stakeholders and interested parties to gain insights into Olema's latest advancements and future endeavors. Following the event, a recording of the presentation will be made available for those unable to attend live.

Understanding Olema Oncology

Olema Oncology is dedicated to transforming the standard of care in breast cancer treatment. The clinical-stage biopharmaceutical company is focused on discovering, developing, and commercializing targeted therapies that aim to improve outcomes for patients affected by this prevalent disease. Their novel therapies are rooted in a comprehensive understanding of endocrine-driven cancers, nuclear receptors, and the mechanisms underlying acquired resistance.

Innovative Product Pipeline

At the forefront of Olema's pipeline is palazestrant (OP-1250), an innovative product candidate that functions as a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). Currently, palazestrant is undergoing a Phase 3 clinical trial known as OPERA-01, which aims to evaluate its effectiveness in treating breast cancer. In addition to this, Olema is actively working on the development of OP-3136, a potent KAT6 inhibitor that is designed to address additional cancer treatment needs.

Company Operations and Future Goals

Olema Oncology is headquartered in San Francisco and has expanded its operations to Cambridge, Massachusetts. With a commitment to patient care, Olema is working diligently to bring innovative therapies to market that will redefine treatment paradigms and improve patients' quality of life. Their focused approach on developing medications with a strong scientific foundation underscores their commitment to leading the charge in breast cancer treatment.

Engaging with Media and Investors

The leadership at Olema, particularly Courtney O'Konek, Vice President of Corporate Communications, plays a crucial role in maintaining open lines of communication with both media and investors. This interaction ensures that the latest developments and insights regarding the company’s initiatives are shared in a timely and efficient manner. Interested individuals can reach out to Courtney via the provided contact information to explore more about Olema's valuable work.

Frequently Asked Questions

What is the focus of Olema Oncology?

Olema Oncology focuses on developing targeted therapies for breast cancer and other endocrine-driven cancers.

Who is presenting at the TD Cowen conference?

Sean P. Bohen, M.D., Ph.D., the President and CEO of Olema, will be giving the presentation.

How can I watch the presentation live?

A live webcast of the presentation will be available on Olema's Investor Relations website.

What is the lead product candidate of Olema Oncology?

The lead product candidate is palazestrant (OP-1250), which is currently in Phase 3 clinical trials.

Where is Olema Oncology headquartered?

Olema Oncology is headquartered in San Francisco, California.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.